Last reviewed · How we verify

IMPAX LABS — Portfolio Competitive Intelligence Brief

IMPAX LABS pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Pyrilamine mepyramine marketed Central Nervous System Stimulant [EPC] Histamine H1 receptor Immunology 1973-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Caraco · 1 shared drug class
  3. Hikma · 1 shared drug class
  4. Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 shared drug class
  5. UCB · 1 shared drug class
  6. University of Colorado, Denver · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for IMPAX LABS:

Cite this brief

Drug Landscape (2026). IMPAX LABS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/impax-labs. Accessed 2026-05-15.

Related